All data are based on the daily closing price as of September 17, 2025
c
Celltrion
068270.KO
122.24 USD
0.05
+0.04%
Overview
Last close
122.24 usd
Market cap
27.49B usd
52 week high
147.00 usd
52 week low
104.55 usd
Target price
158.92 usd
Valuation
P/E
N/A
Forward P/E
31.25
Price/Sales
10.1023
Price/Book Value
2.2973
Enterprise Value
28.79B usd
EV/Revenue
10.5805
EV/EBITDA
36.8299
Key financials
Revenue TTM
2.72B usd
Gross Profit TTM
1.45B usd
EBITDA TTM
797.53M usd
Earnings per Share
N/A usd
Dividend
0.5 usd
Total assets
15.18B usd
Net debt
1.38B usd
About
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. It is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. In addition, the company engages in the wholesale/retail of medicines. The company distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.